Business Description
Milestone Pharmaceuticals Inc
NAICS : 325410
SIC : 3741
ISIN : CA59935V1076
Total Employee Number:
38Description
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.84 | |||||
Equity-to-Asset | 0.1 | |||||
Debt-to-Equity | 3.3 | |||||
Debt-to-EBITDA | -0.82 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -3.48 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -46.6 | |||||
3-Year EBITDA Growth Rate | 19.9 | |||||
3-Year EPS without NRI Growth Rate | 18.4 | |||||
3-Year FCF Growth Rate | 22.1 | |||||
3-Year Book Growth Rate | -41.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 24.25 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 322.66 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.56 | |||||
9-Day RSI | 56.2 | |||||
14-Day RSI | 51.49 | |||||
3-1 Month Momentum % | -17.73 | |||||
6-1 Month Momentum % | -32.95 | |||||
12-1 Month Momentum % | -31.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.13 | |||||
Quick Ratio | 7.92 | |||||
Cash Ratio | 7.69 | |||||
Days Inventory | 19032.9 | |||||
Days Sales Outstanding | 336.88 | |||||
Days Payable | 47978.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -45.8 | |||||
Shareholder Yield % | -9.98 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 98.04 | |||||
Operating Margin % | -3345.24 | |||||
Net Margin % | -3585.62 | |||||
EBITDA Margin % | -3116.82 | |||||
FCF Margin % | -2631.07 | |||||
OCF Margin % | -2615.88 | |||||
ROE % | -425.19 | |||||
ROA % | -67.31 | |||||
ROIC % | -1643.23 | |||||
3-Year ROIIC % | 122.51 | |||||
ROC (Joel Greenblatt) % | -5423.76 | |||||
ROCE % | -66.89 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 53.81 | |||||
PB Ratio | 7.53 | |||||
Price-to-Tangible-Book | 7.53 | |||||
EV-to-EBIT | -0.41 | |||||
EV-to-EBITDA | -0.41 | |||||
EV-to-Revenue | 12.87 | |||||
EV-to-Forward-Revenue | 8.47 | |||||
EV-to-FCF | -0.49 | |||||
| Price-to-Net-Current-Asset-Value | 8.07 | |||||
| Price-to-Net-Cash | 18.83 | |||||
Earnings Yield (Greenblatt) % | -243.9 | |||||
FCF Yield % | -43.82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MIST
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Milestone Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.343 | ||
| EPS (TTM) ($) | -0.68 | ||
| Beta | 2.689 | ||
| 3-Year Sharpe Ratio | -0.01 | ||
| 3-Year Sortino Ratio | -0.01 | ||
| Volatility % | 90.47 | ||
| 14-Day RSI | 51.49 | ||
| 14-Day ATR ($) | 0.076741 | ||
| 20-Day SMA ($) | 1.12475 | ||
| 12-1 Month Momentum % | -31.36 | ||
| 52-Week Range ($) | 1 - 3.06 | ||
| Shares Outstanding (Mil) | 124.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Milestone Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Milestone Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 78 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 08:30 | 1.27 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 1.27 (+0.00%) | ||
| General meeting for 2026 | 2026-06-10 11:00 | 1.21 (-2.42%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ | 2026-05-19 15:00 | 1.46 (-4.58%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 08:30 | 1.90 (-1.55%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 1.90 (-1.55%) | ||
| 25(th) Annual Needham Virtual Healthcare Conference | 2026-04-13 15:45 | 2.02 (-1.46%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-20 08:30 | 1.70 (+1.19%) | ||
| Annual report for 2025 | 2026-03-20 | 1.70 (+1.19%) |
Show
Entries
Milestone Pharmaceuticals Inc Frequently Asked Questions
What is Milestone Pharmaceuticals Inc(MIST)'s stock price today?
The current price of MIST is $1.13. The 52 week high of MIST is $3.06 and 52 week low is $1.00.
When is next earnings date of Milestone Pharmaceuticals Inc(MIST)?
The next earnings date of Milestone Pharmaceuticals Inc(MIST) is 2026-11-12 Est..
Does Milestone Pharmaceuticals Inc(MIST) pay dividends? If so, how much?
Milestone Pharmaceuticals Inc(MIST) does not pay dividend.
Press Release
Articles on Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals (MIST) Launches Phase 3 Trial Amidst High Price-to-Sales Valuation
5 days ago
Milestone Pharmaceuticals (MIST) Rated Overweight with $3 Price Target Amid Market Access Optimism
6 days ago
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers